Perceptive, a top biotech investment firm, is sponsoring the SPAC. The boards of both Arya III and Nautilus have approved the proposed transaction, which is expected to close in the second quarter. The combined company will keep the Nautilus name and will be listed on the Nasdaq under the ticker NAUT.
帕尔和斯坦福教授成立于2016年Parag Mallick, Nautilus is building a combination of hardware and software to more accurately and efficiently quantify the human proteome. The 70-person company, co-located in Seattle and Silicon Valley, has an ambitious plan to change the way therapeutics are developed, seeking to catalyze a new wave of medical treatment.
“We believe that a radical reinvention of proteomics is necessary,” Patel said during an investor presentation Monday. “And we believe that Nautilus has the platform with the potential to revolutionize biomedicine.”
Patel and Mallick will continue leading Nautilus when the merger is completed, along with the existing leadership team.
While it’s now relatively simple and cheap to analyze a genome with a drop of blood, the same progress hasn’t been made with the proteome — and that’s the opportunity Nautilus is looking to capture with what it describes as faster, cheaper, and more precise proteomic technologies.
Part of Nautilus’ secret sauce is the ability to crunch huge amounts of data required when reading a proteome and applying technology such as machine learning. That’s something Patel knows well from his experience at Isilon, a pioneering storage company that went public in 2006 and helped large organizations better manage massive datasets.
There are several use cases for the company’s technology, including therapeutics development and other proteomics applications. A majority of FDA-approved drugs target a protein, and knowing more about the proteome can help make the drug development process more efficient.
In some ways, Nautilus wants to democratize proteomics, similar to how companies such as publicly-traded biotech giant Illumina have done with genomics. The company estimates a total addressable market of more than $25 billion.
鹦鹉螺raised去年增加了7600万系列B轮由Vulcan Capital领导，由已故的Microsoft联合创始人保罗艾伦创建的多亿美元控股公司。Bezos Expeditions，亚马逊创始人Jeff Bezos的VC ARM，也投入了VC，以及VILECTIVE ADVINGS，ANDREESSEN HOROWITZ，Madrona Venture Group等。
安德森、Madrona和火神参与the PIPE, as well as new backers such as RA Capital Management, Ally Bridge Group, Bain Capital Life Sciences, Franklin Templeton Investments, OrbiMed, Alyeska Investment Group, L.P., and Casdin Capital.
上个月鹦鹉螺announcedthree executive hires, including two of Patel’s former colleagues at Isilon. Late last year it also signed its first pharma partnership with Genentech for a pilot study.
鹦鹉螺’ SPAC deal follows a public offering last week for another Seattle biotech startup, Sana, whichraised$587.5 million and saw shares climb 40% on its first day of trading.
Other Seattle-area companies are getting in on the SPAC craze. In December, Seattle home services tech company Porch raised more than $322 millionthrough a merger上周使用PROPTECH收购公司，无线先锋CRAIG MCCAW的西雅图区域SPAC HOLICITY与卫星发射公司Astra合并.